MammaPrint Clinical Utility
Low Risk

MAMMAPRINT+BLUEPRINT
Illuminating Tumor Biology

Agendia's MammaPrint® 70-gene test enables clinicians to identify women* with a genomically Low Risk of recurrence that clinical studies have demonstrated as being able to forgo chemotherapy, yet show benefit with a full 10 years of endocrine therapy.

MAMMAPRINT INDEX



Guiding **Chemotherapy** Decisions

CHEMOTHERAPY DE-ESCALATION CONSIDERATIONS WITH MAMMAPRINT LOW RISK RESULT

	MINDACT LEVEL 1A EVIDENCE	
Total patients (n)	6,693	
Total Clinical High Risk but MammaPrint Low Risk patients	1,551	
DMFS MammaPrint Low Risk, Clinical high risk LN-	**5-Year** **CT:** 95.1% **No CT:** 94.3%	**8-Year** **CT:** 91.7% **No CT:** 89.2%
DMFS MammaPrint Low Risk, Clinical high risk 1-3 LN+	**5-Year** **CT:** 96.0% **No CT:** 95.9%	**8-Year** **CT:** 91.2% **No CT:** 89.9%

MINDACT 8yr FU. Piccart et al 2021. Lancet Oncology

Guiding **Endocrine** Decisions

ENDOCRINE & EXTENDED ENDOCRINE CONSIDERATIONS
WITH MAMMAPRINT LOW RISK RESULT

Endocrine Decisions (Years 1-5)
with MammaPrint Low Risk Result

	STO-3
Treatment	TAM for 2 years, then patients without relapse randomized to 3 additional years or none
Total MammaPrint Low Risk patients *node-negative postmenopausal*	371 (58%)
20 year BCSS	**Treated:** 90% **Untreated:** 80%

STO-3. van't Veer L. et al 2017. BCRT



STO-3. van't Veer L. et al 2017. BCRT

Extended Endocrine Decisions (Years 6-10)
with MammaPrint Low Risk Result

	B-42	IDEAL
Treatment	Randomized to extended letrozole or placebo	Randomized to 2.5 or 5 years of EET w/ letrozole
Total patients (n) (Post-menopausal)	1866	515
Total MammaPrint Low Risk patients	908 (48.6%)	223 (43%)
Absolute Benefit of EET for MammaPrint Low Risk	9.5% 10-Year DFS	9.7% 10-Year BCFI
	Rastogi et al., JCO 2024	van 't Veer et al., JAMA, November 2024

B-42 and IDEAL trials important implications:

- MP is predictive of EET benefit
- MP High Risk patients can avoid potential EET overtreatment
- MP Low Risk patients benefit from EET



Rastogi et al., JCO 2024

SCAN TO LEARN MORE
OR ORDER A TEST

MAMMAPRINT+BLUEPRINT
Illuminating Tumor Biology